ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,467.64
-0.03%
US Tech 100
19,180.00
0.03%
다우존스 지수
39,159.01
0.12%
Bitcoin
61,035.42
-1.25%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 영국
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) 뉴스

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
일자:
정렬 기준:
 검색 관련기사 보기:LSE:HCM
일자시간출처헤드라인심볼기업
2024/06/2617:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2024 HY Financial ResultsLSE:HCMHutchmed (china) Limited
2024/06/2418:30RNS Non-RegulatoryHutchmed (China) Limited Save the Date: HUTCHMED to Present R&D UpdatesLSE:HCMHutchmed (china) Limited
2024/06/2418:00Alliance NewsAlliance NewsIN BRIEF: Hutchmed China notes Takeda obtains EU approval for FruzaqlaLSE:HCMHutchmed (china) Limited
2024/06/2415:00RNS Regulatory NewsHutchmed (China) Limited European Commission Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
2024/06/1718:32Alliance NewsAlliance NewsHutchmed celebrates "promising" results for sovleplenib in ChinaLSE:HCMHutchmed (china) Limited
2024/06/1715:00RNS Non-RegulatoryHutchmed (China) Limited Lancet Publish Phase III ESLIM-01 ResultsLSE:HCMHutchmed (china) Limited
2024/06/0802:13Alliance NewsAlliance NewsIN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506LSE:HCMHutchmed (china) Limited
2024/06/0715:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase I Trial of HMPL-506LSE:HCMHutchmed (china) Limited
2024/06/0315:00RNS Non-RegulatoryHutchmed (China) Limited Nature Medicine Publish Phase III FRUTIGA ResultsLSE:HCMHutchmed (china) Limited
2024/05/3117:30RNS Regulatory NewsHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
2024/05/2415:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Presentations at 2024 ASCO Annual MeetingLSE:HCMHutchmed (china) Limited
2024/05/1801:58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
2024/05/1723:00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
2024/05/1715:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
2024/05/1422:33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
2024/05/1415:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
2024/05/1415:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
2024/05/1021:00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
2024/05/0817:30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
2024/04/2700:09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
2024/04/2621:30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
2024/04/2217:30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
2024/04/0817:30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
2024/04/0517:30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
2024/04/0218:32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
2024/04/0215:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
2024/03/2820:08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2816:00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2219:09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
2024/03/2216:16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
 검색 관련기사 보기:LSE:HCM

최근 히스토리

USOTC
TNTMF
Transition Metals (PK)
NYSE
BKE
Buckle
LSE
50YT
Hsbc Bk. 25
EU
1311T
1311T
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유